Cultivates medicinal mushrooms in Canada. Extracts key compounds from medicinal mushrooms. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Red columns mark years that ended in a loss.
At this burn rate the cash pile isn’t the pressing question — for now, time is on the company’s side.
This company is not turning a profit, so the market is pricing its sales instead: 22.2× for every dollar of annual revenue.
No analyst target is on record for this company.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Revenue Growth: Sales are growing slowly.
An investor who bought at the very peak is down 94% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Sales run at $23K a year. A small number, but proof the product has real buyers.
There is $1.0M in the vault; even if every debt were paid off, $1.0M would remain.
A loss of $237K against $23K in annual sales. And on top of that, sales fell from the year before.
The stock sits at $0.11. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
This stock swings about 2.2 times as much as the market average. Big rallies — and big drops — can both happen fast.
No score published: this stock trades under $10,000 on a typical day, so the price beside it is not one you could reliably act on.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: earnings execution, the revenue breakdown.